Mechanism
KRAS G12D/HLA-C*08:02
Assets acting on this target.
- Class
- HLA-restricted KRAS G12D-targeting autologous engineered T-cell therapy
- Notes
- audit finding #1577 (material); source: https://clinicaltrials.gov/api/v2/studies/NCT06218914
Mechanism
Assets acting on this target.
1 of 1 assets